Barrett M S, Wenzel R P, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City.
Diagn Microbiol Infect Dis. 1992 Sep-Oct;15(7):641-4. doi: 10.1016/0732-8893(90)90043-u.
We measured the in vitro activity of mersacidin (formerly M87-1551) against 183 clinical isolates (vancomycin susceptible) and 12 additional vancomycin-resistant strains of Gram-positive bacteria. The activity for mersacidin increased an average twofold (range, 1.7- to 7.6-fold) in a calcium-enriched medium. The minimum inhibitory concentration (MIC)90 for mersacidin was 8-32 times higher than vancomycin for staphylococci, 4-64 times higher for enterococci, and up to 32 times higher for other organisms tested. The MIC90 for MDL 62873, a comparison compound, was less than or equal to 0.5 micrograms/ml for all species except Staphylococcus haemolyticus (MIC90, 4 micrograms/ml), and it was greater than or equal to 4-fold more active than vancomycin. Against selected vancomycin-resistant strains, mersacidin had MICs greater than or equal to 16 micrograms/ml for enterococci, 4-32 micrograms/ml for Pediococcus, and less than or equal to 2 micrograms/ml for Leuconostoc species. Mersacidin may have some clinical utility in documented infections caused by staphylococci, nonenteric streptococci, Pediococcus, and Leuconostoc.
我们测定了美罗培南（原M87 - 1551）对183株临床分离株（对万古霉素敏感）以及另外12株耐万古霉素革兰氏阳性菌的体外活性。在富含钙的培养基中，美罗培南的活性平均提高了两倍（范围为1.7至7.6倍）。美罗培南对葡萄球菌的最低抑菌浓度（MIC）90比万古霉素高8至32倍，对肠球菌高4至64倍，对其他受试菌高至32倍。对照化合物MDL 62873除对溶血葡萄球菌（MIC90为4微克/毫升）外，对所有菌种的MIC90均小于或等于0.5微克/毫升，其活性比万古霉素高4倍或更高。对于选定的耐万古霉素菌株，美罗培南对肠球菌的MIC大于或等于16微克/毫升，对片球菌为4至32微克/毫升，对明串珠菌属小于或等于2微克/毫升。美罗培南在由葡萄球菌、非肠道链球菌、片球菌和明串珠菌引起的已确诊感染中可能具有一定临床应用价值。
